Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open.
quality of life
tofacitinib
ulcerative colitis
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
05
05
2022
medline:
4
9
2023
pubmed:
16
10
2022
entrez:
15
10
2022
Statut:
ppublish
Résumé
Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We report health-related quality of life (HRQoL) outcomes in patients with ulcerative colitis in the phase 3 open-label, long-term extension study, OCTAVE Open. The Inflammatory Bowel Disease Questionnaire (IBDQ), EuroQoL-5 Dimensions Health Questionnaire, and 36-Item Short Form Survey scores were analyzed up to month (M) 72 in 4 subpopulations: patients in remission at baseline (maintenance remitters) assigned tofacitinib 5 mg twice daily and patients not in remission at baseline (maintenance nonremitters, maintenance treatment failures, and induction nonresponders [IndNRs]) assigned tofacitinib 10 mg twice daily in OCTAVE Open. Data were analyzed overall and stratified by corticosteroid use at baseline, prior tumor necrosis factor inhibitor failure, and prior immunosuppressant failure. Among maintenance remitters and nonremitters, HRQoL outcomes were maintained up to M72: 80.0% and 100.0% of patients had an IBDQ total score ≥170, respectively. At baseline, 7.4% of maintenance treatment failures had an IBDQ total score ≥170, and this increased to 54.3% and 75.0% at M2 and M72, respectively. Corresponding values for IndNRs were 22.6%, 51.0%, and 86.0%. HRQoL outcomes were independent of treatment history. Among patients not in remission at baseline, improvement in EuroQoL-5 Dimensions Health Questionnaire and 36-Item Short Form Survey scores was maintained or achieved by M2, and steady to M72 or M33, with maintenance treatment failures and IndNR subpopulations undergoing the biggest improvements from baseline. A continued favorable impact on HRQoL was revealed with long-term tofacitinib treatment in OCTAVE Open, regardless of baseline remission status or treatment history. (ClinicalTrials.gov; number: NCT01470612). Health-related quality of life was assessed in patients with ulcerative colitis in an open-label, long-term extension study, OCTAVE Open. Patients had sustained beneficial effects on health-related quality of life with long-term tofacitinib treatment, regardless of treatment history/remission status at OCTAVE Open baseline.
Sections du résumé
BACKGROUND
Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We report health-related quality of life (HRQoL) outcomes in patients with ulcerative colitis in the phase 3 open-label, long-term extension study, OCTAVE Open.
METHODS
The Inflammatory Bowel Disease Questionnaire (IBDQ), EuroQoL-5 Dimensions Health Questionnaire, and 36-Item Short Form Survey scores were analyzed up to month (M) 72 in 4 subpopulations: patients in remission at baseline (maintenance remitters) assigned tofacitinib 5 mg twice daily and patients not in remission at baseline (maintenance nonremitters, maintenance treatment failures, and induction nonresponders [IndNRs]) assigned tofacitinib 10 mg twice daily in OCTAVE Open. Data were analyzed overall and stratified by corticosteroid use at baseline, prior tumor necrosis factor inhibitor failure, and prior immunosuppressant failure.
RESULTS
Among maintenance remitters and nonremitters, HRQoL outcomes were maintained up to M72: 80.0% and 100.0% of patients had an IBDQ total score ≥170, respectively. At baseline, 7.4% of maintenance treatment failures had an IBDQ total score ≥170, and this increased to 54.3% and 75.0% at M2 and M72, respectively. Corresponding values for IndNRs were 22.6%, 51.0%, and 86.0%. HRQoL outcomes were independent of treatment history. Among patients not in remission at baseline, improvement in EuroQoL-5 Dimensions Health Questionnaire and 36-Item Short Form Survey scores was maintained or achieved by M2, and steady to M72 or M33, with maintenance treatment failures and IndNR subpopulations undergoing the biggest improvements from baseline.
CONCLUSIONS
A continued favorable impact on HRQoL was revealed with long-term tofacitinib treatment in OCTAVE Open, regardless of baseline remission status or treatment history. (ClinicalTrials.gov; number: NCT01470612).
Health-related quality of life was assessed in patients with ulcerative colitis in an open-label, long-term extension study, OCTAVE Open. Patients had sustained beneficial effects on health-related quality of life with long-term tofacitinib treatment, regardless of treatment history/remission status at OCTAVE Open baseline.
Autres résumés
Type: plain-language-summary
(eng)
Health-related quality of life was assessed in patients with ulcerative colitis in an open-label, long-term extension study, OCTAVE Open. Patients had sustained beneficial effects on health-related quality of life with long-term tofacitinib treatment, regardless of treatment history/remission status at OCTAVE Open baseline.
Identifiants
pubmed: 36242764
pii: 6761656
doi: 10.1093/ibd/izac222
pmc: PMC10472737
doi:
Substances chimiques
tofacitinib
87LA6FU830
Pyrroles
0
Janus Kinase Inhibitors
0
Banques de données
ClinicalTrials.gov
['NCT01470612']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1370-1379Informations de copyright
© 2022 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.
Références
Inflamm Bowel Dis. 2021 Oct 20;27(11):1747-1755
pubmed: 33529314
Aliment Pharmacol Ther. 2020 Oct;52(8):1353-1365
pubmed: 32876349
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Gastroenterology. 1989 Mar;96(3):804-10
pubmed: 2644154
N Engl J Med. 2017 May 4;376(18):1723-1736
pubmed: 28467869
Am J Gastroenterol. 2007 Apr;102(4):794-802
pubmed: 17324131
Inflamm Bowel Dis. 2016 Mar;22(3):752-62
pubmed: 26841224
Aliment Pharmacol Ther. 2022 Feb;55(4):464-478
pubmed: 34854095
Gastroenterology. 2021 Apr;160(5):1570-1583
pubmed: 33359090
Clin Exp Gastroenterol. 2015 Mar 23;8:111-7
pubmed: 25848313
Aliment Pharmacol Ther. 2020 Jan;51(2):271-280
pubmed: 31660640
Aliment Pharmacol Ther. 2018 Jan;47(2):162-175
pubmed: 29205406
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1821-1830.e3
pubmed: 33127596
J Crohns Colitis. 2015 Mar;9(3):284-92
pubmed: 25576752
PLoS One. 2016 Oct 24;11(10):e0165435
pubmed: 27776175
Cochrane Database Syst Rev. 2015 Sep 22;(9):CD008655
pubmed: 26393522
Inflamm Bowel Dis. 2021 Jun 15;27(7):983-993
pubmed: 32794567
J Crohns Colitis. 2021 Jul 5;15(7):1130-1141
pubmed: 33290538
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Clin Gastroenterol Hepatol. 2022 Jan;20(1):116-125.e5
pubmed: 33039585
Inflamm Bowel Dis. 2012 Feb;18(2):201-11
pubmed: 21484965
J Crohns Colitis. 2018 Jan 24;12(2):145-156
pubmed: 29028981